share_log

Needham Reiterates Buy on Harmony Biosciences, Maintains $50 Price Target

Moomoo 24/7 ·  Apr 9 06:24

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $50 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment